Express News | Yifan Pharmaceutical: Aibegesitine α injection has been approved for market launch by the Brazilian National Health Surveillance Agency.

BreakingsDec 20 20:16

Yifan Pharmaceutical (002019.SZ): Ryzneuta's marketing authorization application has been approved by ANVISA.

On December 20, according to Gelonghui, Yifan Pharmaceutical (002019.SZ) announced that it recently learned through the Diário Oficial da União (the Federal Official Gazette of Brazil) that its product, Abeglistat α injection (internal research and development code: F-627, referred to as "Ryzneuta"), has received approval for marketing authorization, allowing it to be sold in Brazil.

Gelonghui FinanceDec 20 20:14

Yifan Pharmaceutical (002019.SZ): The anti-itch ointment has received registration approval in Singapore.

On December 16, Gelonghui reported that Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary SciGen Pte. Ltd. recently received the registration approval for Chinese Patent Medicine issued by the Health Sciences Authority (HSA) of Singapore, allowing the company to exclusively market its anti-itch ointment in Singapore. The anti-itch ointment's main functions are to clear heat and eliminate dampness, dispel wind, and relieve itching. It is used as an adjunct treatment for acute and subacute eczema cases associated with damp-heat or damp obstruction.

Gelonghui FinanceDec 16 19:29

Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.

BreakingsDec 13 21:24

Express News | Yifan Pharmaceutical: A wholly-owned subsidiary's some products are proposed to be selected for the tenth batch of national pharmaceutical centralized procurement.

BreakingsDec 13 19:09

Yifan Pharmaceutical Secures Registration Approval for Neostigmine Methylsulfate Injection

MT NewswiresNov 22 13:31